Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis

References

• Corcia P, Pradat P, Salachas F, et al. Causes of death in a post‐mortem series of ALS patients. Amyotroph Lateral Scler. 2008;9(1):59–62.
   PubMed Web of Science ®Google Scholar
• Abhinav K, Stanton B, Johnston C, et al. Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology. 2007;29(1–2):44–48.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385–390.
   PubMed Web of Science ®Google Scholar
• Li TM, Alberman E, Swash M. Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease. J Neurol Neurosurg Psychiatry. 1988;51(6):778–784.
   PubMed Web of Science ®Google Scholar
• Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17–23.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). In: Cochrane database of systematic reviews. Cochrane Neuromuscular Disease Group. Chichester, UK: John Wiley & Sons, Ltd; 2012.
   Google Scholar
• Peters OM, Ghasemi M, Brown RHJ. Emerging mechanisms of molecular pathology in ALS. J Clin Invest. 1767–79;125(5):2015.
   Google Scholar
• Bastos AF, Orsini M, Machado D, et al. Amyotrophic lateral sclerosis: one or multiple causes? Neurol Int. 2011;3(1):e4.
   PubMedGoogle Scholar
• Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1(5):293–299.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Huss A, Mayer B, et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Front Degener. 2016;18(1–2):112–119.
   PubMed Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79(1):152–158.
   PubMed Web of Science ®Google Scholar
• Otto M, Bowser R, Turner M, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012;13(1):1–10.
   PubMed Web of Science ®Google Scholar
• Sakka L, Coll G, Chazal J. Anatomy and physiology of cerebrospinal fluid. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128(6):309–316.
   PubMed Web of Science ®Google Scholar
• Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta. 2001;310:173–186.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Williams E, Ganchev P, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem. 2005;95(5):1461–1471.
   PubMed Web of Science ®Google Scholar
• Pasinetti GM, Ungar LH, Lange DJ, et al. Identification of potential CSF biomarkers in ALS. Neurology. 2006;66(8):1218–1222.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Nicholl GCB, Henry S, et al. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph Lateral Scler. 2007;8(6):373–379.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Mogel H, Lehmensiek V, et al. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem Res. 2008;33(11):2358–2363.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Lehmensiek V, Mogel H, et al. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010;468(1):23–27.
   PubMed Web of Science ®Google Scholar
• Ryberg H, An J, Darko S, et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve. 2010;42(1):104–111.
   PubMed Web of Science ®Google Scholar
• Mendonça DMF, Pizzati L, Mostacada K, et al. Neuroproteomics: an insight into ALS. Neurol Res. 2012;34(10):937–943.
   PubMed Web of Science ®Google Scholar
• Von Neuhoff N, Oumeraci T, Wolf T, et al. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS One. 2012;7(9):e44401.
   PubMed Web of Science ®Google Scholar
• Varghese AM, Sharma A, Mishra P, et al. Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin Proteomics. 2013;10(1):19.
   PubMed Web of Science ®Google Scholar
• Collins MA, An J, Hood BL, et al. Label-free LC-MS/MS proteomic analysis of cerebrospinal fluid identifies protein/pathway alterations and candidate biomarkers for amyotrophic lateral sclerosis. J Proteome Res. 2015;14(11):4486–4501.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu X, Wu J, et al. Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp Ther Med. 2016;11:2095–2106.
   PubMed Web of Science ®Google Scholar
• Günther R, Krause E, Schümann M, et al. Depletion of highly abundant proteins from human cerebrospinal fluid: a cautionary note. Mol Neurodegener. 2015;10:53.
   PubMed Web of Science ®Google Scholar
• Subramaniyam D, Steele C, Köhnlein T, et al. Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo. Inflamm Res. 2010;59(7):571–578.
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Minthon L, Londos E, et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology. 2007;69(16):1569–1579.
   PubMed Web of Science ®Google Scholar
• Pearl GS, Mullins RE. α1-antitrypsin in cerebrospinal fluid of patients with neurologic diseases. Arch Neurol. 1985;42(8):775–777.
   PubMedGoogle Scholar
• Chen CPC, Chen RL, Preston JE. The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma. Exp Gerontol. 2012;47(4):323–328.
   PubMed Web of Science ®Google Scholar
• Jesse S, Lehnert S, Jahn O, et al. Differential sialylation of serpin A1 in the early diagnosis of Parkinson’s disease dementia. PLoS One. 2012;7(11):e48783.
   PubMed Web of Science ®Google Scholar
• Halbgebauer S, Nagl M, Klafki H, et al. Modified serpinA1 as risk marker for Parkinson’s disease dementia: analysis of baseline data. Sci Rep. 2016;6:26145.
   PubMed Web of Science ®Google Scholar
• Romme Christensen J, Börnsen L, Khademi M, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult Scler J. 2013;19(7):877–884.
   PubMed Web of Science ®Google Scholar
• Han R, Cheng Y, Zhou S, et al. Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with guillain-barré syndrome. J Clin Immunol. 2014;34(1):94–103.
   PubMed Web of Science ®Google Scholar
• Heywood WE, Galimberti D, Bliss E, et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 2015;10:64.
   PubMed Web of Science ®Google Scholar
• Maetzler W, Berg D, Schalamberidze N, et al. Osteopontin is elevated in Parkinson’s disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis. 2007;25(3):473–482.
   PubMed Web of Science ®Google Scholar
• Ganesalingam J, An J, Shaw CE, et al. Combination of neurofilament heavy chain and complement c3 as CSF biomarkers for ALS. J Neurochem. 2011;117(3):528–537.
   PubMed Web of Science ®Google Scholar
• Chiang H, Lyu R, Tseng M, et al. Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clin Chim Acta. 2009;405(1–2):143–147.
   PubMed Web of Science ®Google Scholar
• Lehmensiek V, Süssmuth SD, Brettschneider J, et al. Proteome analysis of cerebrospinal fluid in Guillain–Barré syndrome (GBS). J Neuroimmunol. 2007;185(1):190–194.
   PubMed Web of Science ®Google Scholar
• Maetzler W, Tian Y, Baur SM, et al. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One. 2012;7(10):e48042.
   PubMed Web of Science ®Google Scholar
• Riisøen H. Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer’s disease. Acta Neurol Scand. 1988;78(6):455–459.
   PubMed Web of Science ®Google Scholar
• Zhang H-L, Zhang XM, Mao XJ, et al. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Acta Neurol Scand. 2012;125(2):129–135.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Amari M, Takatama M, et al. Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathol. 2006;112(5):597–603.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Gao L, Wang D, et al. Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Acta Neurologica Scandinavica. 2017;136(2):145–150.
   Web of Science ®Google Scholar
• Lehmensiek V, Süssmuth SD, Tauscher G, et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler. 2007;13(7):840–849.
   PubMed Web of Science ®Google Scholar
• Barrett AJ. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta. 1986;45(11–12):1363–1374.
   PubMedGoogle Scholar
• Abrahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990;268(2):287–294.
   PubMed Web of Science ®Google Scholar
• Abrahamson M, Barrett AJ, Salvesen G, et al. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem. 1986;261(24):11282–11289.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Kaur G, Mi W, et al. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed). 2011;3:541–554.
   PubMedGoogle Scholar
• Okamoto K, Hirai S, Amari M, et al. Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. Neurosci Lett. 1993;162(1–2):125–128.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Hayakawa T, Wakasugi K, et al. Cystatin C protects neuronal cells against mutant copper-zinc superoxide dismutase-mediated toxicity. Cell Death Dis. 2014;5(10):e1497.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen Y, Wei Q, et al. Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis. BMC Neurol. 2016;16(1):173.
   PubMed Web of Science ®Google Scholar
• Tsuji-Akimoto S, Yabe I, Niino M, et al. Cystatin C in cerebrospinal fluid as a biomarker of ALS. Neurosci Lett. 2009;452(1):52–55.
   PubMed Web of Science ®Google Scholar
• Wilson ME, Boumaza I, Lacomis D, et al. Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS One. 2010;5(12):e15133.
   PubMed Web of Science ®Google Scholar
• Mori F, Tanji K, Miki Y, et al. Decreased cystatin C immunoreactivity in spinal motor neurons and astrocytes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2009;68(11):1200–1206.
   PubMed Web of Science ®Google Scholar
• Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics. 2003;3(8):1486–1494.
   PubMed Web of Science ®Google Scholar
• Deng A, Irizarry MC, Nitsch RM, et al. Elevation of cystatin C in susceptible neurons in Alzheimer’s disease. Am J Pathol. 2001;159(3):1061–1068.
   PubMed Web of Science ®Google Scholar
• Nakashima I, Fujinoki M, Fujihara K, et al. Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann Neurol. 2007;62(2):197–200.
   PubMed Web of Science ®Google Scholar
• Rüetschi U, Zetterberg H, Podust VN, et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol. 2005;196(2):273–281.
   PubMed Web of Science ®Google Scholar
• Sanchez JC, Guillaume E, Lescuyer P, et al. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics. 2004;4(8):2229–2233.
   PubMed Web of Science ®Google Scholar
• Carrette O, Burkhard PR, Hughes S, et al. Truncated cystatin C in cerebrospiral fluid: technical artefact or biological process? Proteomics. 2005;5(12):3060–3065.
   PubMed Web of Science ®Google Scholar
• Lehnert S, Costa J, De Carvalho M, et al. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2014;15(5–6):344–350.
   PubMed Web of Science ®Google Scholar
• Levi A, Ferri GL, Watson E, et al. Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol. 2004;24(4):517–533.
   PubMed Web of Science ®Google Scholar
• Alder J, Thakker-Varia S, Bangasser DA, et al. Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci. 2003;23(34):10800–10808.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Lange DJ, Ho L, et al. VGF is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. Int J Med Sci. 2008;5(2):92–99.
   PubMedGoogle Scholar
• Brancia C, Noli B, Boido M, et al. VGF protein and its C-terminal derived peptides in amyotrophic lateral sclerosis: human and animal model studies. PLoS One. 2016;11(10):e0164689.
   PubMed Web of Science ®Google Scholar
• Hölttä M, Minthon L, Hansson O, et al. An integrated workflow for multiplex CSF proteomics and peptidomics—identification of candidate cerebrospinal fluid biomarkers of Alzheimer’s disease. J Proteome Res. 2015;14(2):654–663.
   PubMed Web of Science ®Google Scholar
• Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233(1–2):183–198.
   PubMed Web of Science ®Google Scholar
• Yuan A, Rao MV, Nixon RA, et al. Neurofilaments at a glance. J Cell Sci. 2012;125(14):3257–3263.
   PubMed Web of Science ®Google Scholar
• Boylan K, Yang C, Crook J, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. 2009;111:1182–1191.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Süßmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66(6):852–856.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247–2257.
   PubMed Web of Science ®Google Scholar
• Menke RAL, Gray E, Lu CH, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015;2(7):748–755.
   PubMed Web of Science ®Google Scholar
• Reijn TS, Abdo WF, Schelhaas HJ, et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009;256:615–619.
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 2013–2018;67(5):1996.
   Google Scholar
• Zetterberg H, Jacobsson J, Rosengren L, et al. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol. 2007;14(12):1329–1333.
   PubMed Web of Science ®Google Scholar
• Oeckl P, Jardel C, Salachas F, et al. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotroph Lateral Scler Front Degener. 2016;17(5–6):404–413.
   PubMed Web of Science ®Google Scholar
• Ganesalingam J, An J, Bowser R, et al. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(2):146–149.
   PubMed Web of Science ®Google Scholar
• Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2015;87(1):12–20.
   PubMed Web of Science ®Google Scholar
• Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012;19(12):1561–1567.
   PubMed Web of Science ®Google Scholar
• Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(4):467–472.
   PubMed Web of Science ®Google Scholar
• Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One. 2013;8(9):e75091.
   PubMed Web of Science ®Google Scholar
• Li S, Ren Y, Zhu W, et al. Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis. J Neurol Sci. 2016;367:269–274.
   PubMed Web of Science ®Google Scholar
• Meeter LH, Dopper EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3(8):623–636.
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Skillbäck T, Mattsson N, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73(1):60–67.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Plattner K, Bestwick JP, et al. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler J. 2013;19(12):1597–1603.
   PubMed Web of Science ®Google Scholar
• Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187(6):761–772.
   PubMed Web of Science ®Google Scholar
• Barone R, Sotgiu S, Musumeci S. Plasma chitotriosidase in health and pathology. Clin Lab. 2007;53(5–6):321–333.
   PubMed Web of Science ®Google Scholar
• Sotgiu S, Barone R, Zanda B, et al. Chitotriosidase in patients with acute ischemic stroke. Eur Neurol. 2005;54(3):149–153.
   PubMed Web of Science ®Google Scholar
• di Rosa M, Malaguarnera G, de Gregorio C, et al. Modulation of chitotriosidase during macrophage differentiation. Cell Biochem Biophys. 2013;66(2):239–247.
   PubMed Web of Science ®Google Scholar
• Castellani RJ, Siedlak SL, Fortino AE, et al. Chitin-like polysaccharides in Alzheimer’s disease brains. Curr Alzheimer Res. 2005;2(4):419–423.
   PubMedGoogle Scholar
• Sotgiu S, Musumeci S, Marconi S, et al. Different content of chitin-like polysaccharides in multiple sclerosis and Alzheimer’s disease brains. J Neuroimmunol. 2008;197(1):70–73.
   PubMed Web of Science ®Google Scholar
• Pagliardini V, Pagliardini S, Corrado L, et al. Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J Neurol Sci. 2015;348(1–2):245–250.
   PubMed Web of Science ®Google Scholar
• Lee P, Waalen J, Crain K, et al. Human chitotriosidase polymorphisms G354R and A442V associated with reduced enzyme activity. Blood Cells Mol Dis. 2007;39(3):353–360.
   PubMed Web of Science ®Google Scholar
• Comabella M, Domínguez C, Rio J, et al. Plasma chitotriosidase activity in multiple sclerosis. Clin Immunol. 2009;131(2):216–222.
   PubMed Web of Science ®Google Scholar
• Di Rosa M, Dell’Ombra N, Am Z, et al. Chitotriosidase and inflammatory mediator levels in Alzheimer’s disease and cerebrovascular dementia. Eur J Neurosci. 2006;23(10):2648–2656.
   PubMed Web of Science ®Google Scholar
• Watabe-Rudolph M, Song Z, Lausser L, et al. Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology. 2012;78(8):569–577.
   PubMed Web of Science ®Google Scholar
• Aerts JM, Van Breemen MJ, Bussink AP, et al. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr. 2008;97(457):7–14.
   PubMed Web of Science ®Google Scholar
• Sotgiu S, Piras MR, Barone R, et al. Chitotriosidase and Alzheimer’s disease. Curr Alzheimer Res. 2007;4(3):295–296.
   PubMed Web of Science ®Google Scholar
• Surinova S, Schiess R, Hüttenhain R, et al. On the development of plasma protein biomarkers. J Proteome Res. 2011;10(1):5–16.
   PubMed Web of Science ®Google Scholar
• Muthu M, Vimala A, Mendoza OH, et al. Tracing the voyage of SELDI-TOF MS in cancer biomarker discovery and its current depreciation trend - need for resurrection? Trends Anal Chem. 2016;76:95–101.
   Web of Science ®Google Scholar
• Brechlin P, Jahn O, Steinacker P, et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics. 2008;8(20):4357–4366.
   PubMed Web of Science ®Google Scholar
• Polaskova V, Kapur A, Khan A, et al. High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis. 2010;31(3):471–482.
   PubMed Web of Science ®Google Scholar
• Therrien M, Dion PA, Rouleau GA. ALS: recent developments from genetics studies. Curr Neurol Neurosci Rep. 2016;16(6):59.
   PubMed Web of Science ®Google Scholar